{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:32:23Z","timestamp":1762101143866},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,8]],"date-time":"2011-01-08T00:00:00Z","timestamp":1294444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s11940-010-0111-8","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T04:50:13Z","timestamp":1294375813000},"page":"119-130","source":"Crossref","is-referenced-by-count":32,"title":["Inflammatory Myopathies"],"prefix":"10.1007","volume":"13","author":[{"given":"B. Jane","family":"Distad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,8]]},"reference":[{"key":"111_CR1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00019052-200410000-00006","volume":"17","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC: Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004, 17:561\u2013567.","journal-title":"Curr Opin Neurol"},{"key":"111_CR2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, et al.: Workshop report. 119th ENMC international workshop: Trial: design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003. Naarden, The Netherlands. Neuromusc Dis 2004, 14:337\u2013345.","journal-title":"Neuromusc Dis"},{"issue":"2","key":"111_CR3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"Grable-Esposito P, Katzberg HD, Greenberg SA, et al.: Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41(2):185\u2013190.","journal-title":"Muscle Nerve"},{"key":"111_CR4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00328515","volume":"236","author":"M Vosskamper","year":"1989","unstructured":"Vosskamper M, Korf B, Franke B, et al.: Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated form polymyositis. J Neurol 1989, 236:489\u2013490.","journal-title":"J Neurol"},{"key":"111_CR5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00415-003-1027-y","volume":"250","author":"IM Bronner","year":"2003","unstructured":"Bronner IM, Hoogendijk JE, Wintzen AR, et al.: Necrotizing myopathy, an unusual presentation of a steroid responsive myopathy. J Neurol 2003, 250:480\u2013485.","journal-title":"J Neurol"},{"key":"111_CR6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peters JB: Polymyositis and dermatomyositis: part 1. N Engl J Med 1975, 292:344\u2013347.","journal-title":"N Engl J Med"},{"key":"111_CR7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peters JB: Polymyositis and dermatomyositis: part 2. N Engl J Med 1975, 292:403\u2013407.","journal-title":"N Engl J Med"},{"key":"111_CR8","volume-title":"Inclusion-Body Myositis and Myopathies","year":"1998","unstructured":"Askanas V, Serratrice G, Engel WK (eds.): Inclusion-Body Myositis and Myopathies. Cambridge, UK: Cambridge University Press; 1998."},{"key":"111_CR9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/jnnp.70.5.569","volume":"70","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC: Progress in inflammatory myopathies: good but not good enough. J Neurol Neurosurg Psychiatry 2001, 70:569\u2013573.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"111_CR10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.410400407","volume":"40","author":"AA Amato","year":"1995","unstructured":"Amato AA, Gronseth GS, Jackson CE, et al.: Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1995, 40:581\u2013586.","journal-title":"Ann Neurol"},{"key":"111_CR11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archotol.1992.01880030103021","volume":"118","author":"DH Darrow","year":"1992","unstructured":"Darrow DH, Hoffman HT, Barnes GJ, et al.: Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 1992, 118:313\u2013317.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"111_CR12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mus.880140514","volume":"14","author":"A Verma","year":"1991","unstructured":"Verma A, Bradley WG, Adensina AM, et al.: Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 1991, 14:470\u2013473.","journal-title":"Muscle Nerve"},{"key":"111_CR13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"JT Kissel","year":"1986","unstructured":"Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:331\u2013334.","journal-title":"N Engl J Med"},{"key":"111_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archneur.1991.00530130034016","volume":"48","author":"JT Kissel","year":"1991","unstructured":"Kissel JT, Halterman RK, Rammohan KW, Mendell JR: The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991, 48:26\u201330.","journal-title":"Arch Neurol"},{"key":"111_CR15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0022-510X(89)90228-1","volume":"94","author":"M Visser De","year":"1989","unstructured":"De Visser M, Emslie-Smith AM, Engel AG: Early ultrastructural alterations in adult dermatomyositis: capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989, 94:181\u2013192.","journal-title":"J Neurol Sci"},{"issue":"5","key":"111_CR16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, et al.: Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57(5):664\u2013678.","journal-title":"Ann Neurol"},{"issue":"11","key":"111_CR17","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","volume":"65","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Bradshaw EM, Pinkus JL, et al.: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65(11):1782\u20131787.","journal-title":"Neurology"},{"key":"111_CR18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archneur.1991.00530240033013","volume":"48","author":"JR Mendell","year":"1991","unstructured":"Mendell JR, Sahenk Z, Gales T, et al.: Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991, 48:1229\u20131234.","journal-title":"Arch Neurol"},{"key":"111_CR19","unstructured":"Greenberg SA: Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009, 983\u2013989. This is an excellent recent review of IBM, with a focus on its pathogenesis and an emphasis on the limitations of the evidence supporting beta-amyloid-mediated muscle injury as a cause of this disease."},{"issue":"10","key":"111_CR20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/jnnp.2008.169375","volume":"80","author":"AA Amato","year":"2009","unstructured":"Amato AA, Barohn RJ: Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009, 80(10):1060\u20131068.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"111_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch TW, Worthington JW, Combs JJ, et al.: Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980, 92:365\u2013369.","journal-title":"Ann Intern Med"},{"key":"111_CR22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch TW: Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 1981, 24:45\u201348.","journal-title":"Arthritis Rheum"},{"key":"111_CR23","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993\u20132000.","journal-title":"N Engl J Med"},{"key":"111_CR24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, et al.: Results and long term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467\u2013474.","journal-title":"Arthritis Rheum"},{"key":"111_CR25","first-page":"2498","volume":"27","author":"SM Al-Mayouf","year":"2000","unstructured":"Al-Mayouf SM, Laxer RM, Schneider R, et al.: Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000, 27:2498\u20132503.","journal-title":"J Rheumatol"},{"issue":"3","key":"111_CR26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/CRIAI:29:3:255","volume":"29","author":"MC Dalakas","year":"2005","unstructured":"Dalakas MC: Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes. Clin Rev Allergy Immunol 2005, 29(3):255\u2013269.","journal-title":"Clin Rev Allergy Immunol"},{"key":"111_CR27","first-page":"2855","volume":"27","author":"KA Qushmaq","year":"2000","unstructured":"Qushmaq KA, Chalmers A, Esdaile JM: Cyclosporine A in the treatment of refractory adult polymyositis\/dermatomyositis: population-based experience in six patients and literature review. J Rheumatol 2000, 27:2855\u20132859.","journal-title":"J Rheumatol"},{"issue":"1","key":"111_CR28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Yamada H, Yamasaki M, et al.: Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology (Oxford) 2007, 46(1):124\u2013130.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"111_CR29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143(6):763\u2013767.","journal-title":"Arch Dermatol"},{"key":"111_CR30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601\u2013607.","journal-title":"Arthritis Rheum"},{"key":"111_CR31","first-page":"3844","volume":"62","author":"CV Oddis","year":"2010","unstructured":"Oddis CV, Reed AM, Aggarwal R, et al.: The RIM Study Group: Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM)\u2014The RIM study. Arthritis Rheum 2010, 62:3844.","journal-title":"Arthritis Rheum"},{"key":"111_CR32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.45.7.1302","volume":"45","author":"RJ Barohn","year":"1995","unstructured":"Barohn RJ, Amato AA, Sahenk Z, et al.: Inclusion body myositis: explanation for poor response to therapy. Neurology 1995, 45:1302\u20131304.","journal-title":"Neurology"},{"key":"111_CR33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL: Drug therapy of idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379\u2013387.","journal-title":"Am J Med"},{"key":"111_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","volume":"72","author":"RL Leff","year":"1993","unstructured":"Leff RL, Miller FW, Hicks J, et al.: The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993, 72:225\u2013235.","journal-title":"Medicine"},{"key":"111_CR35","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","volume":"43","author":"SA Soueidan","year":"1993","unstructured":"Soueidan SA, Dalakas M: Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993, 43:876\u2013879.","journal-title":"Neurology"},{"key":"111_CR36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman B, Fujii M, et al.: A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001, 56:323\u2013327.","journal-title":"Neurology"},{"key":"111_CR37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, et al.: Treatment of inclusion body myositis with IVIG; a double-blind, placebo-control study. Neurology 1997, 48:712\u2013716.","journal-title":"Neurology"},{"key":"111_CR38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walker","year":"2000","unstructured":"Walker MC, Lochmuller H, Toepfer M, et al.: High dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo controlled study. J Neurol 2000, 247:22\u201328.","journal-title":"J Neurol"},{"issue":"3","key":"111_CR39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","volume":"51","author":"UA Badrising","year":"2002","unstructured":"Badrising UA, Maat-Schieman ML, Ferrari MD, et al.: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51(3):369\u2013372.","journal-title":"Ann Neurol"},{"issue":"7","key":"111_CR40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","volume":"58","author":"SB Rutkove","year":"2002","unstructured":"Rutkove SB, Parker RA, Nardin RA, et al.: A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002, 58(7):1081\u20131087.","journal-title":"Neurology"},{"issue":"2","key":"111_CR41","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","volume":"61","author":"C Lindberg","year":"2003","unstructured":"Lindberg C, Trysberg E, Tarkowski A, et al.: Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003, 61(2):260\u2013262.","journal-title":"Neurology"},{"issue":"4","key":"111_CR42","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","volume":"63","author":"Muscle Study Group","year":"2004","unstructured":"Muscle Study Group: Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004, 63(4):718\u2013720.","journal-title":"Neurology"},{"issue":"4","key":"111_CR43","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/art.22687","volume":"57","author":"C Hallengren","year":"2007","unstructured":"Hallengren C, Richards S, Thomas EL, et al.: Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 57(4):694\u2013702.","journal-title":"Arthritis Rheum"},{"key":"111_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0960-8966(98)00126-6","volume":"9","author":"J DeBleecker","year":"1999","unstructured":"DeBleecker J, Meire V, Declercq W, Van Aken E: Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999, 9:239\u2013246.","journal-title":"Neuromuscul Disord"},{"issue":"3\u20134","key":"111_CR45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"GJ Hengstman","year":"2008","unstructured":"Hengstman GJ, De Bleecker JL, Feist E, et al.: Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59(3\u20134):159\u2013163.","journal-title":"Eur Neurol"},{"issue":"1","key":"111_CR46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/03009740903096622","volume":"39","author":"U Holzer","year":"2010","unstructured":"Holzer U, van Royen-Kerkhof A, van der Torre P, et al.: Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010, 39(1):88\u201392.","journal-title":"Scand J Rheumatol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-010-0111-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-010-0111-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-010-0111-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T01:25:03Z","timestamp":1637112303000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-010-0111-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1007\/s11940-010-0111-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,8]]}}}